Immatics N.V. has announced the completion of its business combination with Arya Sciences Acquisition Corporation. The Immatics shares and warrants are now traded under the symbol “IMTX” and the symbol “IMTXW” on the Nasdaq Capital Market.
Transactional value
The proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors.
Immunotherapies
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. Arya Sciences Acquisition Corporation is a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Immatics’ management team, led by CEO Harpreet Singh, Ph.D., will continue to run the combined company.
CMS Team
An international CMS team supported Immatics on all legal aspects of the transaction in the Netherlands and Germany. The Dutch team was led by Martijn van der Bie and Clair Wermers and the German team by Stefan-Ulrich Müller and Tilman Weichert.
